REQUEST A DEMO
总计
USD $0.00
搜索更多公司

China Sxt Pharmaceuticals Inc. (中国)

主营业务: 医药制剂制造
全名: China Sxt Pharmaceuticals Inc. 公司更新日期: 2024.11.20
购买我们的报告为这家公司 USD 29.95 最近财务数据:2024 可有的: 英语 & 中文 下载示例的报告

The Company, a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China.
The Company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The Company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors.
HISTORY
2017 - The Company is a holding company incorporated in British Virgin Islands on July 4, 2017. The Company is headquartered in Taizhou, China.
- On July 21, 2017, the Company wholly owned subsidiary China SXT Group Limited (“SXT HK”) was incorporated in Hong Kong.
2019 On January 3, 2019, The Company s ordinary shares commenced trading on the Nasdaq Capital Market under the symbol of “SXTC.”

总部
178 Taidong Rd North
台州; 浙江; 邮编: 225300

联系方式: 购买China Sxt Pharmaceuticals Inc.报告以查看信息。

网站: http://www.sxtchina.com

基本信息
员工总数:
购买China Sxt Pharmaceuticals Inc.报告以查看信息。
流通股:
购买China Sxt Pharmaceuticals Inc.报告以查看信息。
财务审计师:
购买China Sxt Pharmaceuticals Inc.报告以查看信息。
成立日期:
2017
主要管理人员
购买此报告以查看信息。
Chief Executive Officer
购买此报告以查看信息。
Chief Financial Officer
购买此报告以查看信息。
Director/Member of the Board
购买此报告以查看信息。
Outside Director
购买此报告以查看信息。
Outside Director
所有权明细
购买此报告以查看信息。
12.19%
购买此报告以查看信息。
11.5%
购买此报告以查看信息。
4.47%
下属公司
China Sxt Group Limited (中国香港特别行政区)
Jiangsu Su Xuan Tang Pharmaceutical Co. Ltd.
Taizhou Su Xuan Tang Biotechnology, Co. Ltd.
公司业绩
图表中的财务价值可在之后获得China Sxt Pharmaceuticals Inc.报告购买。
寻找的不仅仅是一个公司的报告吗?

EMIS公司简介是一个更大的信息服务的一部分,它结合了公司,行业和国家数据和分析在超过125个新兴市场.

请求EMIS服务的演示
主要财务重点
年增长百分比对于以当地货币近两年USD。绝对财务数据包含在购买报告中。
销售净额
-2.23%
营业收入总计
-2.23%
营业利润
53.19%
EBITDA
64.72%
净利润(亏损)
47.78%
总资产
-21.75%
权益总额
-5.18%
经营利润率
144.25%
销售收益率
140.22%
股本收益率
18.15%
负债股权比率
-6.17%
速动比率
0.2%
现金比率
0.16%

查看更多信息, 申请试用

购买这家公司报告
需要定期访问公司,行业或国家/地区的信息吗?